Figure 1 | Leukemia

Figure 1

From: MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia

Figure 1

MIR551B expression in stem and progenitor cells in normal bone marrow and survival analysis of MIR551B in AML. (a) MIR551B expression in the different stem and progenitor cell populations in normal bone marrow determined by quantive PCR with reverse transcription (n=4). HSC (Lin-CD34+CD38-CD90+CD45RA-), MPP (Lin-CD34+CD38−CD90−CD45RA−), CMP (Lin-CD34+CD38+CD123+CD45RA−), GMP (Lin−CD34+CD38+CD123+CD45RA+), MEP (Lin-CD34+CD38+CD123-CD45RA-), monocytes (FSChighSSCintCD14+CD34-CD19-CD3-) and lymphocytes (FSClowSSClowCD19+/CD3+CD34−CD14−). Statistical significance was calculated using Mann–Whitney test. (*) differential expression of indicated population compared with HSC and MPP cells (P<0.05). Error bars denote ±s.e.m. (be) Survival plots from the discovery cohort for OS (b) and RFS (c) and the TCGA cohort for OS (d) and RFS (e). For both discovery and TCGA cohorts, patients were 60 years of age. Patients with a PML-RARA translocation were excluded from the analysis. Determination of optimal cutoff for MIR551B in the discovery (b, c) and the TCGA cohort (d, e) was done with Cutoff Finder using log rank test (Supplementary Figure 2).

Back to article page